APA (7th ed.) Citation

Fiorillo, M., Scatena, C., Naccarato, A. G., Sotgia, F., & Lisanti, M. P. (2021). Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase. Cell death and differentiation, 28(9), 2797-2817. https://doi.org/10.1038/s41418-021-00788-x

Chicago Style (17th ed.) Citation

Fiorillo, Marco, Cristian Scatena, Antonio Giuseppe Naccarato, Federica Sotgia, and Michael P. Lisanti. "Bedaquiline, an FDA-approved Drug, Inhibits Mitochondrial ATP Production and Metastasis in Vivo, by Targeting the Gamma Subunit (ATP5F1C) of the ATP Synthase." Cell Death and Differentiation 28, no. 9 (2021): 2797-2817. https://doi.org/10.1038/s41418-021-00788-x.

MLA (9th ed.) Citation

Fiorillo, Marco, et al. "Bedaquiline, an FDA-approved Drug, Inhibits Mitochondrial ATP Production and Metastasis in Vivo, by Targeting the Gamma Subunit (ATP5F1C) of the ATP Synthase." Cell Death and Differentiation, vol. 28, no. 9, 2021, pp. 2797-2817, https://doi.org/10.1038/s41418-021-00788-x.